PRECISION BIOSCIENCES INC: Lynx1 Capital Management LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Lynx1 Capital Management LP amended its Schedule 13G filing on Precision BioSciences Inc., updating its passive stake disclosure with the SEC under accession number 0000902664-26-004574. The filing does not disclose a change in share count, leaving the exact size of Lynx1's position unclear from the headline. The amendment matters because 13G updates signal shifts in institutional ownership that can influence governance and liquidity in a small-cap biotech. Investors will watch for the specific ownership percentage and any subsequent 13D or 13G filings that clarify Lynx1's intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Lynx1 Capital Management LP, Precision Biosciences Inc